Klivira
Request demo

Streamlining Centene Kesimpta Prior Authorization Workflows

Navigating the complexities of Centene Kesimpta prior authorization is a critical operational challenge for revenue cycle and prior authorization teams. Klivira provides the automation infrastructure to streamline these high-volume requests.

Kesimpta (ofatumumab) is an anti-CD20 monoclonal antibody prescribed for relapsing forms of multiple sclerosis (RMS), a condition often requiring long-term, high-cost specialty drug therapy. Due to its cost and specific indications, Kesimpta is consistently a target for prior authorization across commercial, Medicare Advantage, and Medicaid managed care plans. Centene's federated structure, encompassing brands like Ambetter and Wellcare, alongside numerous state Medicaid subsidiaries, adds layers of complexity to the PA process, demanding precise, plan-specific engagement.

Centene's Federated Approach to Prior Authorization for Specialty Drugs

Centene Corporation operates through a network of state-licensed subsidiaries and national brands, including Ambetter for ACA marketplace plans and Wellcare/Allwell for Medicare Advantage. Each subsidiary, such as Fidelis Care, Health Net, Meridian, or Sunshine Health, maintains its own provider portal and distinct prior authorization processes. For specialty drugs like Kesimpta, understanding the specific plan (e.g., Ambetter, Wellcare, or a state Medicaid plan) and the administering subsidiary is paramount for accurate submission.

Kesimpta Prior Authorization Submission Channels

For Kesimpta, prior authorization submission channels vary based on benefit design. If Kesimpta is covered under the pharmacy benefit, requests typically route through Envolve Pharmacy Solutions, Centene's in-house pharmacy services entity, and can often be submitted via ePA platforms like CoverMyMeds or Surescripts. If Kesimpta is considered a medical benefit drug (e.g., administered in a clinical setting), submissions are processed through the specific Centene subsidiary's provider portal or via X12 278 transactions through clearinghouses.

Key Considerations for Centene Kesimpta Policies

  • **Subsidiary-Specific Policies**: Each Centene subsidiary publishes its own clinical policy and coverage determination library. There is no single 'Centene' medical policy; verify the specific subsidiary's policy for Kesimpta.
  • **Formulary and Step Therapy**: Kesimpta's formulary placement, step therapy requirements, and quantity limits are determined at the individual plan level (e.g., Ambetter, Wellcare, or state Medicaid plan) and are subject to the subsidiary's specific drug lists.
  • **Clinical Criteria**: Centene subsidiaries commonly leverage InterQual criteria for medical necessity reviews. For specialty drugs, policies may also reference established guidelines from organizations like the NCCN compendium, where applicable.
  • **Medicaid State Rules**: For Centene's Medicaid managed care plans, prior authorization criteria cannot be more restrictive than the state Medicaid agency's coverage rules for Kesimpta.

Turnaround Times and CMS-0057-F Compliance

Prior authorization decision timeframes for Kesimpta under Centene plans vary. Medicaid lines are governed by state Medicaid agency rules, while Wellcare and Allwell Medicare Advantage plans adhere to CMS-mandated organization determination timeframes (14 calendar days standard, 72 hours expedited). Centene's broad scope across Medicaid, Medicare Advantage, and ACA marketplace plans positions it as an impacted payer under CMS-0057-F, which phases in 72-hour standard and 24-hour expedited PA decision requirements.

Common Denial Reasons and Appeal Pathways for Kesimpta

Denials for Kesimpta prior authorization from Centene subsidiaries often stem from medical necessity criteria not being met, insufficient documentation, or the service being rendered without a required authorization. Appeal pathways are subsidiary-specific; Medicaid managed care appeals are subject to state Medicaid agency requirements, including fair hearing rights, while Medicare Advantage plans follow the CMS-mandated 5-level appeal structure for organization determinations. Robust documentation and timely submission are critical for successful appeals.

Frequently asked questions

How do Centene's multiple brands affect Kesimpta prior authorization?

Centene operates through state subsidiaries (e.g., Health Net, Meridian) and national brands (Ambetter, Wellcare). Each entity manages its own PA processes, portals, and clinical policies for Kesimpta. You must identify the specific plan and subsidiary to ensure accurate submission and policy adherence.

Which Centene entity handles pharmacy benefit prior authorizations for Kesimpta?

For Kesimpta covered under the pharmacy benefit, prior authorizations are typically handled by Envolve Pharmacy Solutions, Centene's in-house PBM. Submissions can often be made via their provider portal or common ePA platforms like CoverMyMeds and Surescripts.

Are Kesimpta prior authorization policies consistent across all Centene Medicaid plans?

No. While Centene subsidiaries administer Medicaid plans, their PA policies for Kesimpta are subject to the specific state Medicaid agency's rules. Criteria and processes can vary significantly by state, and the subsidiary's policy cannot be more restrictive than the state's coverage rules.

How does Klivira help with Centene Kesimpta prior authorization?

Klivira automates the prior authorization process by integrating with EMRs and connecting to various payer submission channels, including Centene's subsidiary portals and ePA platforms. This streamlines data extraction, submission, and status tracking, reducing manual effort and accelerating approvals for Kesimpta.

What are common reasons for Kesimpta PA denials from Centene plans?

Common denial reasons include not meeting medical necessity criteria outlined in the subsidiary's policy, insufficient clinical documentation to support the request, or failure to obtain prior authorization before service. Denials can also occur if the drug is not on the specific plan's formulary or if step therapy requirements are not met.

Related coverage

Other kesimpta prior authorization by payer

Other kesimpta prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo